Business
SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025
Press release – No.13 / 2025 SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025 Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity. “Obesity is one of th
About this update from Zealand Pharma A/s
[{"type":"image","alt":"Zealand Pharma","displaySize":"","headline":null,"caption":"Zealand Pharma","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":121,"url":"https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6gUCOEdJjLHihlE.VvDQtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2OTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2567d307984f8639b4a7711f51c64eff","width":300,"height":121}},"lazy":false},{"type":"text","content":"Press release – No.13 / 2025","length":28,"tagName":"p"},{"type":"text","content":"SAVE THE DATE: Zealand Pharma to host Capital Markets Day in London on December 11, 2025","length":88,"tagName":"p"},{"type":"text","content":"Copenhagen, Denmark, September 11, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announced that it will host a Capital Markets Day in London on December 11, 2025, featuring presentations from management and external experts in obesity.","length":360,"tagName":"p"},{"type":"text","content":"“Obesity is one of the greatest healthcare challenges of our time, and we are in the very early stages of a rapidly evolving market for weight loss therapies. With a differentiated pipeline targeting obesity and related comorbidities, strong partnerships supporting our leading programs, and a solid financial foundation, we are well positioned to realize our vision of becoming a key player in the future management of obesity.” said Adam Steensberg, President and Chief Executive Officer at Zealand Pharma.","length":508,"tagName":"p"},{"type":"text","content":"“Zealand Pharma is now entering a catalyst-rich chapter from a position of strength. At our Capital Markets Day in December, we look forward to setting the stage for upcoming Phase 2 data with petrelintide and Phase 3 data with survodutide, while also sharing insights into our strategy on driving the next wave of innovation.”","length":327,"tagName":"p"},{"type":"text","content":"External experts and thought leaders in the obesity field who will present alongside Zealand Pharma’s management team include Jonathan Roth, PhD, a metabolic researcher and pioneer in amylin-leptin biology; Dr. Louis Aronne, Professor of Clinical Medicine at We...